Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor

Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, Dall’igna P, Coffin CM, Martines A, Bonaldi L, De Salvo GL, Zanovello P, Rosalo A (2013) Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). PLoS One 8:E80456 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2011) Pre- and post- translational regulation of osteopontin in cancer. J Cell Commun Signal 5:111–122 Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Wurl P, Taubert H, Vordemark D (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10:132 Brady SW, Zhang J, Tsai MH, Yu D (2015) PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther 16:402–411 Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF (2005) Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther 4:1336–1341 Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestol K, Smeland S, Danielsen HE, Mertens F, Lothe RA (2009) Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol 11:514–528 Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA (2006) Survivin-directed RNA interference cocktail is a potent suppressor of tumor growth in vivo. J Med Genet 43:119–128 Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the italian and german soft tissue sarcoma cooperative group. J Clin Oncol 23:8422–8430 Cordon-Cardo C (1995) Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545–560 Cunha KSG, Caruso AC, de Faria PAS, da Silva LE, Pires AR, Geller M, Lopes VS, Moura-Neto RS (2012) Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clinics 67:963–968 Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006–2021 Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, Hayes J, Altura RA. Survivin (2005) survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92:359–365 Farnebo L, Tiefenböck K, Ansell A, Thunell LK, Garvin S, Roberg K (2013) Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer 133:1994–2003 Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E (2007) Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 26:5098–5106 Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, Zhu H, Wang Z, Li J, Wang L, Wang B, Ren G, Ji T, Tu W, Yang X, Qiu W, Mao L, Zhang Z, Chen W (2011) CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One 6:e26399 Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B, Mariani L, Carli M, Bisogno G, Cechetto G, De Salvo GL, Casanova M, Vannoesel MM, Kelsey A, Stevens MC, Devidas M, Pappo AS, Spunt SL (2011) Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer 47:724–731 Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57:1634–1637 Ikeguchi M, Sakatani T, Ueta T, Kaibara N (2001) Cyclin D1 expression and retinoblastoma gene protein (pRb) expression in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 127:531–536 Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Paladins N (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38:2362–2370 Ito H, Duxbury M, Benoit E, Farivar RS, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE (2004) Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun 318:594–600 Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T (2005) Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 28:565–568 Jha K, Shukla M, Pandey M (2011) Survivin expression and targeting in breast cancer. Surg Oncol 21:125–131 Karpinsky G, Fatyga A, Krawczyk MA, Chamera M, Sande N, Szmyd D, Izycka-Swieszewska E, Bien E (2017) Osteopontin: its potential role in cancer of children and young adults. Biomark Med 11:389–402 Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92–95 Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M, Cordon-Cardo C (1998) Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 4:2377–2382 Kindblom LG, Ahlden M, Meis-Kindblom JM, Stenman G (1995) Immunohistochemical and molecular analysis of p53, MDM 2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 427:19–26 Knowles LM, Gurski LA, Engel C, Gnarra JF, Maranchie JK, Pilch J (2013) Integrin αvβ3 and fibronectin upregulate slug in cancer cells to promote clot invasion and metastasis. Cancer Res 73:6175–6184 Kolberg M, Høland M, Agesen TH, Brekke HR, Liestol K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA (2013) Survival meta-analyses for > 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 15:135–147 Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM (1999) Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 155:1855–1860 Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, Revuz J, Creange A, Levy E, Lantieri L, Zeller J, Wolkenstein P (2001) Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 137:908–913 Levy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, Parfait B, Wolkenstein P, Vidaud M, Bieche I (2004) Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 3:20 Partridge M, Costea DE, Huang X (2007) The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 36:1123–1138 Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881 Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ (2002) Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86:886–892 Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT (2001) Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 96:159–165 Shintani M, Okazaki A, Masuda T, Kawada M, Ishizuka M, Doki Y, Weinstein IB, Imoto M (2002) Overexpression of cyclin DI contributes to malignant properties of esophageal tumor cells by increasing VEGF production and decreasing Fas expression. Anticancer Res 22:639–647 Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER, COG Ewing Sarcoma Biology Committee (2013) Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the children’s oncology group. Front Oncol 3:141 Sohier P, Luscan A, Lloyd A, Ashelford K, Laurendeau I, Briand-Suleau A, Vidaud D, Ortonne N, Pasman E, Upadhyaya M (2017) Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. Genes Chromosom Cancer 56:421–426 Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179–184 Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127–134 Treuner J, Gross U, Maas E et al (1991) Results of the treatment of malignant schwannoma: a report from the German soft tissue sarcoma group (CWS). Med Pediatr Oncol 19:399 Upadhyaya M, Osborn MJ, Maynard J, Kim MR, Tamanoi F, Cooper DN (1997) Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 99:88–92 Weber GF, Lett GS, Haubein NC (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103:861–869 Xing N, Qian J, Bostwick D, Bergstralh E, Young CY (2001) Neuroendocrine cells in human prostate over-express the anti- apoptosis protein survivin. Prostate 48:7–15 Yang K, Hitomi M, Stacey DW (2006) Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div 1:32 Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5:65–72 Zehou O, Fabre E, Zelek L, Sbidian E, Ortonne N, Banu E, Wolkenstein P, Valeyrie-Allanore L (2013) Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis 8:127 Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, Viskochil DH (2003) Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 27:1337–1345